Mirati Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Mirati Therapeutics

09/05/2023 23:01

* Mirati Therapeutics Inc  MRTX.OQ  reported a quarterly
adjusted
loss of $3.18​​ per share for the quarter ended in March. The
mean expectation of fifteen analysts for the quarter was for a
loss of $3.55 per share.
    * Revenue rose 910.9% to $7.17 million from a year ago;
analysts
expected $4.78 million. 
    * Mirati Therapeutics Inc's reported EPS for the quarter was
a
loss of $3.18​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Mirati Therapeutics Inc shares had risen by 24.7% this
quarter and gained 2.3% so far this year.
    * The company reported a quarterly loss of $184.59 million.
    * Wall Street's median 12-month price target for Mirati
Therapeutics Inc is $65.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -3.55          -3.18          Beat
 Dec. 31 2022      -3.55          -3.51          Beat
 Sep. 30 2022      -3.48          -3.09          Beat
 Jun. 30 2022      -3.49          -3.18          Beat